User:Brim/stuff

Stuff to add:
 * Chamberlain prodedure
 * ACOSOG Z0050 (PET for Lung ca)
 * cyrotherapy - Jewel THompson effect, Argon
 * ICRU publications 38/50/62
 * Prostate MRI: T2 best for visualizing prostate gland, T1 for showing post-bx hemorrhage, can use T1 or T2 for LN
 * American Urologic Association (AUA) stage for prostate
 * [training.seer.cancer.gov/ss]
 * MRI: Choline/Creatinine ratio versus Citrate. In cancer, citrate is lowered, and choline/creat is increased
 * MRI: diffusion coefficient decreased in tumor
 * Prostate: T3, include all SV in PTV
 * Prostate: RTOG P-0126, 79.2 Gy vs 70.2, Int Risk
 * Prostate: ext/int iliac LN. common iliac uncommon. presarcal uncommon.
 * Look up: Radiol 211: 815-828, 1991 - cross sectional nodal anatomy
 * ASTRO 2004: LN relationship to vessels (prostate)
 * Prostate "standard" pelvic field: up to L4/L5
 * Treatment planning: EUD (equivalent uniform dose), TCP/NTCP (biological cost function), Lyman - sigmoid curve
 * Treatment planning: score, uncomplicated tumor control S=T(1-P1)*(1-P2)
 * Langer et al, Kallman et al.
 * EUD: Niemierco and Mohan
 * EUD=[volume*dose^a]^(1/a)... where a=exponent. if a>>0, EUD trends toward max dose.  if a<<0 trends toward min dose
 * inverse planning algorithms:
 * exhausive search, 1960s
 * simulated annealing (Kirkpatrick 1983, Gemen 1984, Aarts 1985, Webb 1989)
 * filtered backprojection - based on inverse CT technique, Fourier transform. but often gives negative doses which aren't possible
 * L.Xing, Med PHys 25, 1845-49 - iterative method
 * genetic algorithms
 * GIST - KIT tyrosine kinase receptor, binds growth factor
 * SARCOMA:
 * Rosenberg 1982, NCI - amp vs surg/xrt
 * Pisters, MSKCC, JCO 1996 - surg vs surg/xrt
 * Yang, NCI, 1998
 * O'Sullivan NCIC, Lancet 2002 - pre-op vs post-op
 * LR/OS/Regional/Distant control - same for pre/post-op (already metastatic?). post-op has worse grade 3/4 fibrosis (36% vs 23% for preop)
 * fractures 10% at 60-66 Gy (postop) vs 2% for preop 50 Gy
 * preop more wound complications
 * tumor cells >1cm from tumor in 1/3 of cases -- need for large margins
 * HODGKIN LYMPHOMA (correct name)
 * Rye 1966, WHO 2001 (added lymphocyte rich classical HL)
 * use ABVD chemo + IF-XRT 30-36 Gy
 * early stage: extended field + ABVD - high risk of 2nd malignancy, but good cause-specific survival (overall survival is less)
 * Milan 1990-1996, EFRT v IFRT (30-36 Gy) x 4 cycles chemo
 * EORTC H8F
 * Engent JCo 21: 3601, 2003
 * new std of care is short course chemo + IF-RT
 * MALT LYMPHOMA (stomach) - treated like low grade
 * stomach 18 Gy AP/PA, boost obliques to 36 Gy off kidneys
 * new disease - described in 1980s
 * 1/3 have diffuse disease (Stage III-IV)
 * if treat H.pylori may regress. response can take 6 months. assay C-14 urea breath test to follow response, not antibodies
 * Tsang, PMH, JCO 2003, 21:4157
 * 100% control w XRT


 * BURKITT'S LYMHOMA
 * "starry sky"
 * BCL-2 negative usually
 * CNS: RTOG 95-08
 * defn of "conformity index" (by Paddick)
 * GK: trigeminal neuralgia, 75 Gy
 * RPA classification for GBM, Curran 1993 - I to VI
 * RPA for mets
 * RTOG 93-05 - GBM... RT+BCNU vs GK then RT+BCNU
 * RTOG 80-07: neutrons for GBM

NEED TO FIX:
 * At RTOG page, 78-03 and 76-15 have same PMID. Which is correct? RTOG 76-15 need ref.

Miscellaneous info
Wikibook stats: http://wikistics.falsikon.de/latest/wikibooks/en (found here)